Loading...
ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury
BACKGROUND: In contrast with various pre-clinical studies, recent clinical trials suggest that high dose erythropoietin (EPO) treatment following kidney transplantation does not improve short-term outcome and that it even increases the risk of thrombotic events. ARA290 is a non-erythropoietic EPO de...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3567997/ https://ncbi.nlm.nih.gov/pubmed/23302512 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-9 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|